154 related articles for article (PubMed ID: 33905271)
1. Pharmacokinetics, toxicological and clinical aspects of ulipristal acetate: insights into the mechanisms implicated in the hepatic toxicity.
Dinis-Oliveira RJ
Drug Metab Rev; 2021 Aug; 53(3):375-383. PubMed ID: 33905271
[TBL] [Abstract][Full Text] [Related]
2. An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids.
Kang S; Brinker A; Jones SC; Dimick-Santos L; Avigan MI
Drug Saf; 2020 Dec; 43(12):1267-1276. PubMed ID: 32647996
[TBL] [Abstract][Full Text] [Related]
3. Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program.
Donnez J; Arriagada P; Marciniak M; Larrey D
Expert Opin Drug Saf; 2018 Dec; 17(12):1225-1232. PubMed ID: 30460871
[TBL] [Abstract][Full Text] [Related]
4. Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis.
Gatti M; Poluzzi E; De Ponti F; Raschi E
Drug Saf; 2020 Dec; 43(12):1277-1285. PubMed ID: 32748236
[TBL] [Abstract][Full Text] [Related]
5. Which is the destiny of ulipristal acetate for uterine fibroids? A commentary on the Italian medicines agency (AIFA) pronouncements.
Indraccolo U; Conzadori S; Greco P
Recenti Prog Med; 2019 Feb; 110(2):98-99. PubMed ID: 30843536
[TBL] [Abstract][Full Text] [Related]
6. What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate?
Pourcelot AG; Capmas P; Laberge P; Fernandez H
J Gynecol Obstet Hum Reprod; 2020 Apr; 49(4):101688. PubMed ID: 31972353
[TBL] [Abstract][Full Text] [Related]
7. Acute liver failure requiring transplantation: A possible link to ulipristal acetate treatment?
Dinis-Oliveira RJ; Vieira DN
Basic Clin Pharmacol Toxicol; 2021 Sep; 129(3):278-282. PubMed ID: 34187080
[TBL] [Abstract][Full Text] [Related]
8. Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and/or adenomyosis.
Hong YH; Han SJ; Lee D; Kim SK; Jee BC
J Obstet Gynaecol Res; 2019 Apr; 45(4):865-870. PubMed ID: 30675965
[TBL] [Abstract][Full Text] [Related]
9. Acute liver failure requiring transplantation caused by ulipristal acetate.
Meunier L; Meszaros M; Pageaux GP; Delay JM; Herrero A; Pinzani V; Dominique HB
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):e45-e49. PubMed ID: 32146092
[TBL] [Abstract][Full Text] [Related]
10. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
11. Long-term medical management of uterine fibroids with ulipristal acetate.
Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.
Donnez J; Hudecek R; Donnez O; Matule D; Arhendt HJ; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Terrill P; Osterloh I; Loumaye E
Fertil Steril; 2015 Feb; 103(2):519-27.e3. PubMed ID: 25542821
[TBL] [Abstract][Full Text] [Related]
13. Risk-efficacy balance of ulipristal acetate compared to surgical alternatives.
Middelkoop MA; Bet PM; Drenth JPH; Huirne JAF; Hehenkamp WJK
Br J Clin Pharmacol; 2021 Jul; 87(7):2685-2697. PubMed ID: 33341097
[TBL] [Abstract][Full Text] [Related]
14. Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya.
Mozzanega B
J Hepatol; 2021 Mar; 74(3):750-751. PubMed ID: 33271158
[No Abstract] [Full Text] [Related]
15. Ulipristal acetate (Esmya): restrictions on use.
Drug Ther Bull; 2018 Nov; 56(11):127. PubMed ID: 30297449
[No Abstract] [Full Text] [Related]
16. Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience.
Del Forno S; Degli Esposti E; Salucci P; Leonardi D; Iodice R; Arena A; Raimondo D; Paradisi R; Seracchioli R
Gynecol Endocrinol; 2020 May; 36(5):445-447. PubMed ID: 31646908
[TBL] [Abstract][Full Text] [Related]
17. Ulipristal acetate versus leuprolide acetate for uterine fibroids.
Donnez J; Tomaszewski J; Vázquez F; Bouchard P; Lemieszczuk B; Baró F; Nouri K; Selvaggi L; Sodowski K; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):421-32. PubMed ID: 22296076
[TBL] [Abstract][Full Text] [Related]
18. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
19. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA's review of liver injury risk: Unfortunate timing during the Covid-19 pandemic!
Rozenberg S; Revercez P; Fastrez M; Vandromme J; Bucella D
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():300-302. PubMed ID: 32650189
[TBL] [Abstract][Full Text] [Related]
20. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
